Cochrane group skeptical about latest Roche pledges

Cochrane group skeptical about latest roche pledges
Following requests from Cochrane researchers, Roche has pledged to release full clinical study reports for Tamiflu, although there appear to be conditions attached, according to correspondence published in BMJ.

(HealthDay)—Following requests from Cochrane researchers, Roche has pledged to release full clinical study reports for Tamiflu, although there appear to be conditions attached, according to correspondence published in BMJ.

Peter Doshi, Ph.D., from the Johns Hopkins University School of Medicine in Baltimore, along with colleagues from the Cochrane group, recently corresponded with Roche as part of the 's open data campaign designed to encourage Roche to honor its 2009 commitment to make the full clinical study reports for 10 trials of Tamiflu available for independent review.

Noting that Roche recently pledged to release full clinical study reports as part of the data transparency program, the authors question these new promises. Roche plans to allow researchers access to a secure system, following agreement, rather than the requested independent review. Three of the four advisors chosen to lead Roche's advisory board, which will grant access to data, have recent financial ties to Roche. In addition, there has been no attempt to correct the scientific record following the 2003 Roche-authored paper claiming the opposite of the U.S. conclusion that has not been shown to prevent serious bacterial complications of influenza.

"Despite our repeated requests for those data, has yet to provide even a single full study report," Doshi writes. "We are independent scientists, not regulators. Doing our own analysis, not dictated by others, is key to what makes us independent."

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

Tamiflu touted for child use

Nov 16, 2007

The maker of the anti-viral Tamiflu said the drug is effective for treatment and prevention of influenza in young children.

Recommended for you

Mirabegron for overactive bladder: Added benefit not proven

6 hours ago

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products ...

Novartis Japan admits concealing drug side effects

Sep 01, 2014

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

User comments